Barclays downgrades Merck KGaA stock rating to Equalweight on weak outlook

Barclays downgraded Merck KGaA to Equalweight from Overweight, reducing its price target to EUR120 from EUR150, following disappointing second-quarter results primarily driven by "very challenging" conditions and one-off issues in its Electronics business. Despite strong performance in Process Solutions, the German company again lowered its fiscal year 2025 guidance due to the deteriorating Electronics outlook, divestment of Surface Solutions, and increased foreign exchange headwinds. Barclays subsequently cut its FY25-27 sales forecasts by 2% and EBITDA pre estimates by 2-3%, positioning its FY25 projections for both metrics approximately 1% below Bloomberg consensus.

Analysis

Barclays has downgraded Merck KGaA to Equalweight from Overweight and reduced its price target to EUR120 from EUR150, citing disappointing second-quarter results. The downgrade is primarily driven by "very challenging" market conditions and one-off issues within the company's Electronics (EL) business. This weakness prompted Merck KGaA to lower its fiscal year 2025 guidance for a second time, factoring in the deteriorating EL outlook, the divestment of its Surface Solutions unit, and adverse foreign exchange movements. While the company's Process Solutions (PS) segment remains a bright spot, maintaining a book-to-bill ratio above 1x, and margin expectations in Life Science and Healthcare have improved, these positives were insufficient to prevent the guidance cut. In response, Barclays has trimmed its own forecasts, reducing its FY25-27 sales estimates by 2% and EBITDA pre estimates by 2-3%. Barclays' new projections for FY25 sales (EUR21.1 billion) and EBITDA pre (EUR6.0 billion) now sit approximately 1% below Bloomberg consensus, signaling a more pessimistic outlook than the broader market.

Key Decisions for Investors

• Given the downgrade to Equalweight and the significant price target reduction by Barclays, investors should consider reassessing any overweight positions in Merck KGaA.
• The persistent and deteriorating weakness in the Electronics segment is the primary risk driver; closely monitor this division's performance in upcoming quarters for any signs of stabilization or further decline.
• Investors should note that Barclays' revised estimates are now below consensus, indicating a potential for further downward revisions from other analysts, which could place additional pressure on the stock.
• Evaluate the offsetting strength in the Process Solutions, Life Science, and Healthcare segments, as their performance will be critical in mitigating the negative impact from the Electronics business and foreign exchange headwinds.